During angiogenesis, endothelial cell migration is coordinated by integrin‐mediated contact with the extra‐cellular matrix (ECM), coupled with receptor tyrosine kinase signalling to regulate dynamic cytoskeletal and plasma membrane reorganization. A recent paper by Vitorino et al ([2015][1]) defined a new MAP4K4–moesin–talin–β1‐integrin pathway that could be therapeutically exploited to suppress pathologic angiogenesis.\r\r [1]: #ref-12
CITATION STYLE
Saharinen, P., & Ivaska, J. (2015). Blocking integrin inactivation as an anti‐angiogenic therapy. The EMBO Journal, 34(10), 1293–1295. https://doi.org/10.15252/embj.201591504
Mendeley helps you to discover research relevant for your work.